Key Takeaways
- PDS Biotechnology’s stock maintains a “buy” rating from HC Wainwright with a target price of $21.00.
- Recent analyses show mixed ratings, with StockNews.com downgrading to “sell” and B. Riley lowering the target price to $7.00.
- Institutional ownership has increased, with significant acquisitions in the company’s stock during the fourth quarter.
Stock Performance Overview
PDS Biotechnology (NASDAQ:PDSB) received a reaffirmed “buy” rating from HC Wainwright, with analysts placing a price target of $21.00 per share. However, other reports suggest a varying outlook on the stock’s potential. Notably, StockNews.com recently downgraded PDSB from a “hold” to a “sell” rating. Meanwhile, B. Riley reduced its price target on PDSB from $9.00 to $7.00, while still issuing a “buy” rating.
MarketBeat indicates that PDS Biotechnology currently holds an average rating of “Moderate Buy,” with an expected price target of approximately $11.67. As of last Friday, the company’s stock opened at $1.23, reflecting a 52-week low of $1.13 and a high of $6.00. The stock also shows a 50-day moving average of $1.49 and a 200-day moving average of $2.35. The firm has a market capitalization of $46.98 million and a negative PE ratio of -1.06.
Institutional Investment Activity
Recent activity among institutional investors reflects growing engagement with PDS Biotechnology. Notable investments include a new stake by Raymond James Financial, worth $26,000, and another by Jane Street Group valued at $58,000. Marshall Wace LLP increased its holdings by 38.4%, owning 39,024 shares after adding 10,837 shares. Additionally, Virtu Financial acquired $89,000 worth of stock, while Two Sigma Investments significantly boosted its stake by 273.5%, now holding 65,732 shares valued at $107,000. Currently, institutional investors and hedge funds own about 26.84% of PDS’s shares.
About PDS Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies in the U.S. Its principal product candidate, PDS0101 (HPV16), is designed as a first-line treatment for recurrent or metastatic head and neck cancers as well as human papillomavirus-related malignancies.
The content above is a summary. For more details, see the source article.